IN8bio Inc. (INAB)
IN8bio Inc. (INAB) Stock Price, Analysis & Data
| Bid | 0.74 |
| Market Cap | 9.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -18.98M |
| Beta | 0.28 |
| EPS (ttm) | -1.3 |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.03 |
| P/B (ttm) | 0.43 |
| P/S (ttm) | n/a |
| Earnings Date | Aug 7, 2025 |
| Ask | 1.14 |
| Volume | 90,158 |
| Avg. Volume (20D) | 57,670 |
| Open | 1.07 |
| Previous Close | 1.05 |
| Day's Range | 0.88 - 1.07 |
| 52-Week Range | 0.88 - 2.73 |
| Analyst | Strong Buy |
| Price Target | 5.5 (450.00%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About INAB
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical tria...
Financial Performance
In 2025, IN8bio's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -19.44M, a decrease of -36.13%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for INAB stock is "Strong Buy". The 12-month stock price forecast is 5.5, which is upside of 450% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
